AKT1 and neoplasm: The mammalian target of rapamycin (mTOR) inhibitor, sirolimus inhibits PEL cell growth in a murine xenograft model [7], but which paradoxically induces expression of the serine/threonine kinase Akt and tumor cell growth, resulting in treatment failures [8].